

Abstract

The present invention belongs to the pharmaceutical field, and provides the pharmaceutically acceptable salts of the compound (*S*)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-*N*-(morpholin-2-ylmethyl)pyrido[3,4-*b*]pyrazin-5-amine and the crystalline forms thereof, the solvates and the
5 crystalline forms thereof, the pharmaceutical compositions comprising the same as well as the methods of preparing the same and the use thereof.

Figure 1